Alvotech Hf and DSH hope to get an adalimumab biosimilar approved in the United States, Europe, and selected Southeast Asia markets.
Two European companies provided an update on their plans for bringing an adalimumab biosimilar to market in the United States, Europe, and selected Southeast Asia markets.
Alvotech Hf, of Reykjavik, Iceland, and DKSH, of Zurich, Switzerland, said they have entered into an exclusive license partnership for the commercialization of AVT02, a biosimilar to AbbVie’s Humira, a leading drug for the treatment of several autoimmune diseases, including rheumatoid arthritis, ankylosing spondlytis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Chron disease. Humira had worldwide sales of $18.4 billion in 2017.
DKSH, although based in Zurich, specializes in helping companies market their products and services in the Asia-Pacific region, where the DKSH is active in 36 emerging countries.
“Through the partnership, Alvotech Hf gains access to DKHS’s strong commercial network, which will ultimately benefit patients who will get better access to high-quality biosimilar medicines,” Mark Levick, chief executive officer of Alvotech Hf, said.
The companies said an approval application for AVTO2 will be filed with the European Medicines Agency and the FDA in the second half of 2020.
There are 5 adalimumab biosimilars to Humira that have been approved in the US market, none of which is expected to be commercialized until 2023, owing to deals negotiated as a result of AbbVie’s exclusivity rights.
Several adalimumab biosimilars launched in Europe for the first time in 2018, following Humira patent expirations in 2017. Stronger patent filings in the US have been attributed to the earlier EU launches.
Dozens of companies around the world have adalimumab biosimilars in development, including in India, Japan, Singapore, China, and the Republic of Korea.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Pharmacokinetic Modeling Proposes Cost-Effective Dosing for Adalimumab, Etanercept Biosimilars
October 12th 2024A UK cohort study used drug concentration samples from rheumatoid arthritis patients starting the adalimumab biosimilar Amgevita and the etanercept biosimilar Benepali to simulate drug levels under standard and alternate dosing schedules, suggesting that personalized dosing could reduce costs while potentially increasing efficacy.